Market Research Report
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2019
|Published by||Global Markets Direct||Product code||363124|
|Published||Content info||85 Pages
Delivery time: 1-2 business days
|C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2019|
|Published: April 29, 2019||Content info: 85 Pages||
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.
C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology, Central Nervous System, Gastrointestinal, Respiratory and Immunology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Metastatic Colorectal Cancer, Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Colon Cancer, Colorectal Cancer, Graft Versus Host Disease (GVHD), Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis and Prostate Cancer.
The latest report C-C Chemokine Receptor Type 5 - Pipeline Review, H1 2019, outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.